Previous close | 21.05 |
Open | 20.80 |
Bid | 21.25 |
Ask | 22.00 |
Strike | 60.00 |
Expiry date | 2025-03-21 |
Day's range | 20.80 - 21.10 |
Contract range | N/A |
Volume | |
Open interest | 28 |
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.